Sponsored By

Lilly
Interview with the Innovators

Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer

Interview with the Innovators
ESMO Early Breast Cancer

This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.

Video Library
Nadia Harbeck, MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, Germany

Featuring:

Interview with the Innovators Presents:
Emerging Data in Early Breast Cancer from ESMO 2023

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.

Related Items

Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this fifth installment, Ms Carroll discusses strategies for managing adverse events associated with abemaciclib, emphasizing the importance of patient involvement and personalized care. She underscores the value of maintaining open communication and regular touchpoints with patients to address concerns, build trust, and ensure adherence to therapy. These strategies aim to improve the quality of life for patients on abemaciclib.
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
By Heather Moore, PharmD, BCOP, CPP
Interview with the Innovators
Video Library
In this fourth installment, Dr Moore shares strategies for optimizing abemaciclib treatment through dose escalation and proactive toxicity management. She emphasizes patient education on managing common side effects and highlights the importance of ongoing patient engagement through touchpoints and clear communication to ensure successful treatment outcomes.
Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?